Clinical Trial Detail

NCT ID NCT02737501
Title ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Ariad Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Brigatinib

Crizotinib

Age Groups: adult

Additional content available in CKB BOOST